Other substances

mAb 2-36

A human monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

mAb 2-36 is a human monoclonal antibody that was selected due to its affinity for SARS-CoV-2 Spike protein RBD. It was identified in a screening of memory B cells of COVID-19 convalescent patients (Liu et al., 2020).

Synonyms

2-36

 

Supporting references

Link Tested on Impact factor Notes Publication date
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Spike protein Animal model In vitro Antibody 		in vitro binding assay; Vero cells; golden Syrian hamsters; SARS-CoV-2 strain USA-WA1/2020 42.78

Neutralized SARS-CoV-2 live and Spike-pseudotyped virus in vitro.

 Jul/22/2020
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Spike protein Spike variant Protein factor In vitro Antibody Mixed substance 		Vero E6 cells; patient sera; SARS-CoV-2 live virus (WA1, B.1.1.7, and B.1.351 strains); (VSV) SARS-CoV-2 Spike pseudoviruses (various strain/mutations) 49.96

The antibody retains its activity against the B.1.351 strain in vitro. 

 Mar/08/2021

AI-suggested references

Link Publication date
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
Nov/28/2021
Export (.csv)